Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 25 , ISSUE 7 ( July, 2021 ) > List of Articles

Original Article

Addition of Valerian and Lemon Balm Extract to Quetiapine Reduces Agitation in Critically Ill Patients with Delirium: A Pilot Randomized Clinical Trial

Babak Alikiaie, Erfan Shahmoradi, Afsaneh Yekdaneh, Sarah Mousavi

Citation Information : Alikiaie B, Shahmoradi E, Yekdaneh A, Mousavi S. Addition of Valerian and Lemon Balm Extract to Quetiapine Reduces Agitation in Critically Ill Patients with Delirium: A Pilot Randomized Clinical Trial. Indian J Crit Care Med 2021; 25 (7):785-790.

DOI: 10.5005/jp-journals-10071-23854

License: CC BY-NC 4.0

Published Online: 07-07-2021

Copyright Statement:  Copyright © 2021; The Author(s).


Background: This study was pointed to evaluate the efficacy and safety of valerian and lemon balm additional to the quetiapine in critically ill patients with delirium and agitation. Methods: We conducted a randomized, double-blind, placebo-controlled study. Fifty-three adult intensive care unit (ICU) patients (according to ICU Confusion Assessment Method scores) who were treated for delirium received quetiapine and Neurogol syrup (a combination of valerian and lemon balm) or placebo 5 mL every 12 hours for five consecutive days. Improvement in agitation according to the Richmond Sedation and Restlessness Scale was considered the main outcome. Results: The trial was completed for 53 patients (27 in the treatment group and 26 in the placebo group). The baseline characteristics between the groups were similar. In the treatment group, the number of agitated patients was significantly reduced and the difference was statistically significant (p = 0.000). Compared with the placebo group, the length of ICU stay in the treatment group was significantly reduced (p = 0.001). The Glasgow Coma Scale improved significantly at the end of day 5 (p = 0.04). There was no statistical difference in the improvement of delirium between the study groups (p = 0.14). Neurogol syrup was well tolerated. Conclusion: The addition of Neurogol to quetiapine (a combination of valerian and lemon balm) can reduce agitation and shorten the length of stay in the ICU without adverse effects. Clearly, more research is still needed to investigate the role of herbal medicines in ICUs and their efficacy and safety.

  1. Krewulak KD, Stelfox HT, Leigh JP, Ely EW, Fiest KM. Incidence and prevalence of delirium subtypes in an adult ICU: a systematic review and meta-analysis. Crit Care Med2018;46(12):2029–2035.DOI: 10.1097/CCM.0000000000003402.
  2. Tang LL. ICU delirium: aconcept analysis. TMR Integr Nurs 2018;2(1):18–26. DOI: 10.12032/TMRIN20180310.
  3. Celis-Rodríguez E, Cortés JD, Bolívar YC, González JC, Pinilla DI, Záccaro LF, et al. Evidence-based clinical practice guidelines for the management of sedoanalgesia and delirium in critically ill adult patients. Med Intensiva (English Edition)2020;44(3):171–184.DOI: 10.1016/j.medin.2019.07.013.
  4. Blair GJ, Mehmood T, Rudnick M, Kuschner WG, Barr J. Nonpharmacologic and medication minimization strategies for the prevention and treatment of ICU delirium: a narrative review. J Intensive Care Med 2019;34(3):183–190. DOI: 10.1177/0885066618771528.
  5. Nikooie R, Neufeld KJ, Oh ES, Wilson LM, Zhang A, Robinson KA, et al. Antipsychotics for treating delirium in hospitalized adults: a systematic review. Ann Intern Med2019;171(7):485–495.DOI: 10.7326/M19-1860.
  6. Zaal IJ, Devlin JW, Hazelbag M, Klouwenberg PMK, van der Kooi AW, Ong DS, et al. Benzodiazepine-associated delirium in critically ill adults. Intensive Care Med 2015;41(12):2130–2137.DOI: 10.1007/s00134-015-4063-z.
  7. Ng K, Shubash C, Chong J. The effect of dexmedetomidine on delirium and agitation in patients in intensive care: systematic review and meta-analysis with trial sequential analysis. Anaesthesia2019;74(3):380–392.DOI: 10.1111/anae.14472.
  8. Levy I, Attias S, Ben-Arye E, Bloch B, Schiff E. Complementary medicine for treatment of agitation and delirium in older persons: a systematic review and narrative synthesis. Int J Geriatr Psychiatry 2017;32(5):492–508. DOI:10.1002/gps.4685.
  9. Matsumoto-Miyazaki J, Ushikoshi H, Miyata S, Miyazaki N, Nawa T, Okada H, et al. Acupuncture and traditional herbal medicine therapy prevent deliriumin patients with cardiovascular disease in intensive care units. Am J Chin Med 2017;45(02):255–268. DOI: 10.1142/S0192415X17500161.
  10. Bannon L, McGaughey J, Verghis R, Clarke M, Mc Auley DF, Blackwood B. The effectiveness of non-pharmacological interventions in reducing the incidence and duration of delirium in critically ill patients: a systematic review and meta-analysis. Intensive Care Med 2019;45(1):1–12.DOI: 10.1007/s00134-018-5452-x.
  11. Ke L, Wang J, Ma Z, Chen B, Wang L, Gong J, et al. Non-pharmacological treatment of intensive care unit delirium. Am J Nurs Sci 2019;8(3): 119–128.DOI: 10.11648/j.ajns.2019 0803.17.
  12. Moradkhani H, Sargsyan E, Bibak H, Naseri B, Sadat-Hosseini M, Fayazi-Barjin A, et al. Melissa officinalis L., a valuable medicine plant: are view. J Med Plant Res 2010;4(25):2753–2759. DOI: 10.5897/JMPR.9000881.
  13. López V, Martín S, Gómez-Serranillos MP, Carretero ME, Jäger AK, Calvo MI. Neuroprotective and neurological properties of Melissa officinalis. Neurochem Res 2009;34(11):1955–1961.DOI: 10.1007/s11064-009-9981-0.
  14. Buchwald-Werner S, Vazquez I. Effects of a Melissa officinalis special extract on mood and cognitive function. Planta Med2015;81(16):SL5C_01. DOI: 10.15171/jhp.2019.19
  15. Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi A, Khani M. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial. J Neurol Neurosurg Psychiatry2003;74(7):863–866.DOI:10.1136/jnnp.74.7.863.
  16. Miraj S, Azizi N, Kiani S. A review of chemical components and pharmacological effects of Melissa officinalis L. Der Pharmacia Lettre2016;8(6):229–237.
  17. Shakeri A, Sahebkar A, Javadi B. Melissa officinalis L.–areview of its traditional uses, phytochemistry and pharmacology. J Ethnopharmacol2016;188:204–228.DOI: 10.1016/j.jep.2016.05.010.
  18. Dastmalchi K, Ollilainen V, Lackman P, af Gennäs GB, Dorman HD, Järvinen PP, et al. Acetylcholinesterase inhibitory guided fractionation of Melissa officinalis L. Bioorg Med Chem 2009;17(2):867–871. DOI: 10.1016/j.bmc.2008.11.034.
  19. Plushner SL. Valerian: Valeriana officinalis. Am J Health-system Pharm2000;57(4):328–335.DPO: 10.1093/ajhp/57.4.328.
  20. Murti K, Kaushik M, Sangwan Y, Kaushik A. Pharmacological properties of Valeriana officinalis– a review. Pharmacology2011;3:641–646.
  21. Sheikhani A, Kholdi N, Mokhtari M. An overview of the most effective tranquilizer herbs. J Basic Clin Pathophysiol 2017;5(2):27–34.DOI: 10.22070/JBCP.2017.2498.1078.
  22. Gusmao-Flores D, Salluh JIF, Chalhub RÁ, Quarantini LC. The confusion assessment method for the intensive care unit (CAM-ICU) and intensive care delirium screening checklist (ICDSC) for the diagnosis of delirium: a systematic review and meta-analysis of clinical studies. Crit Care 2012;16(4):R115.DOI: 10.1186/cc11407.
  23. Ely EW, Truman B, Shintani A, Thomason JW, Wheeler AP, Gordon S, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA2003;289(22):2983–2991.DOI: 10.1001/jama.289.22.2983.
  24. Zolfaghari M, Arbabi M, Pedram Razi S, Biat K, Bavi A. Effectiveness of a multifactor educational intervention on delirium incidence and length of stay in patients with cardiac surgery. J Hayat 2012;18(1):67–78.
  25. Heidari A, Dianati M, Mousavi G. Prevalence of delirium, its related factors and short-term outcomes in ICU wards of Kashan Shahid-Beheshti and Isfahan Kashani hospitals during 2012-2013. Feyz J Kashan Univ Med Sci 2014;18(1).
  26. Ghafari S, Esmaeili S, Aref H, Naghibi F, Mosaddegh M. Qualitative and quantitative analysis of some brands of valerian pharmaceutical products. Stud Ethno-Med2009;3(1):61–64.DOI:10.1080/09735070.2009.11886339.
  27. Watson K, Hatcher D, Good A. A randomised controlled trial of Lavender (Lavandula angustifolia) and Lemon Balm (Melissa officinalis) essential oils for the treatment of agitated behaviour in older people with and without dementia. Complementary Ther Med 2019;42:366–373.DOI: 10.1016/j.ctim.2018.12.016.
  28. Elliott MS, Abuhamdah S, Huang L, Perry EK, Ballard C, Lees G, et al. P1–435: essential oils as potential treatment for agitation in severe dementia: Elucidation of the pharmacological mechanism of Melissa and Lavender oils. Alzheimers Dement2006;2:S225–S.
  29. Andreatini R, Sartori VA, Seabra ML, Leite JR. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res 2002;16(7):650–654.DOI: 10.1002/ptr.1027.
  30. Trompetter I, Krick B, Weiss G. Herbal triplet in treatment of nervous agitation in children. Wien Med Wochenschr 2013;163(3–4):52–57.DOI:10.1007/s10354-012-0165-1.
  31. Hosker C, Ward D. Hypoactive delirium. BMJ2017;357. DOI: 10.1136/bmj.j2047.
  32. O'Keeffe ST, Lavan JN. Clinical significance of delirium subtypes in older people. Age and ageing. 1999;28(2):115–119.DOI: 10.1093/ageing/28.2.115.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.